EGFR and neoplasm: Novel maintenance approaches in the MODUL or FOCUS-4 trials already incorporated more sophisticated stratified concepts recognizing the molecular portrait of the tumor at the end of induction phase (e.g., HER2+EGFR blockade or BRAF inhibitor+Capecitabin+EGFR inhibitor) (110, 111).